Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an indication extension of Darzalex – daratumumab – subcutaneous co-formulated with Enhanze in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma. This approval follows the indication extension approval for daratumumab-VRd in October 2024, for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- EC approves subcutaneous RYBREVANT in combination with LAZCLUZE
- Halozyme: Bristol Myers receives positive CHMP opinion for Opdivo/Enhanze
- Halozyme Announces Retirement of Chief Technical Officer
- Buy Rating for Halozyme: Potential Revenue Boost from Patent Dispute and Licensing Opportunities
- Buy Rating for Halozyme: Strategic Positioning and Intellectual Property Strengths Amid Patent Dispute